Clinical Trial Update: A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

A Phase I pediatric trial of IMC-A12 (cixutumumab) in combination with temsirolimus for recurrent or refractory solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Stem Neoplasms
• Glioma
• Pinealoma

Drugs mentioned

• IMC-A12 (cixutumumab)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain Stem Neoplasms, Glioma | Phase 1 | Status: WITHDRAWN